CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Blood

Volumn 112, Issue 12, 2008, Pages 4683-4689

  Ho, Allen W ^a   Hatjiharissi, Evdoxia ^a,b   Ciccarelli, Bryan T ^a   Branagan, Andrew R ^a   Hunter, Zachary R ^a   Leleu, Xavier ^a,b   Tournilhac, Olivier ^a,b   Xu, Lian ^a   O'Connor, Kelly ^a   Manning, Robert J ^a   Santos, Daniel Ditzel ^a,b   Chemaly, Mariana ^a   Patterson, Christopher J ^a   Soumerai, Jacob D ^a   Munshi, Nikhil C ^b,c   McEarchern, Julie A ^d   Law, Che Leung ^d   Grewal, Iqbal S ^d   Treon, Steven P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CD27 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; MONOCLONAL ANTIBODY; CD70 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN FUNCTION; ARTICLE; BONE MARROW; CELL LINE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN CELL; LYMPHOCYTE; MAST CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCID MOUSE; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PLASMA CELL; PROTEIN BINDING; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD27; ANTIGENS, CD70; CASE-CONTROL STUDIES; CELLS, CULTURED; HUMANS; MAST CELLS; MICE; MICE, SCID; PLASMA CELLS; PROTEIN BINDING; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54149093014     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-04-084525     Document Type: Article

References (39)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30:110-115.
2. Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
4. Tischendorf W, Hartmann F. Waldenström's macroglobulinemia associated with hyperplasia of the tissue mast-cells. Acta Hematol. 1950;4:374-383.
5. Waldenström J. Macroglobulinaemia. Acta Haematol. 1958;20:33-39.
6. Wilkins BS, Buchan SL, Webster J, Jones DB. Tryptase-positive mast cells accompany lymphocytic as well as lymphoplasmacytic lymphoma infiltrates in bone marrow trephine biopsies. Histopathology 2001;39:150-155.
7. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:187-195.
8. Ditzel Santos D, Tournilhac O, Xu Lian Kutok J, et al. B-lymphocyte stimulator protein (BLYS) is expressed by bone marrow mast and lymphoplasmacytic cells in Waldenstrom's macroglobulinemia, and provides signaling for growth, survival and IgM secretion [abstract]. Blood. 2004;104: 917a. Abstract 3358.
9. Tournilhac O, Ditzel Santos D, Xu Lian Kutok J, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006;17:1275-1282.
10. Ho AW, Hatjiharissi E, Branagan A, et al. Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's macroglobulinemia [abstract]. Proc ASCO. 2006;24:102S. Abstract 2509.
11. Hunter ZR, Boxer M, Kahl B, Patterson CJ, Soumerai JD, Treon SP. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079 [abstract]. Proc ASCO. 2006;24:427S. Abstract 7523.
12. Soumerai JD, O'Connor KE, Ioakimidis LM, et al. Imatinib mesylate (Gleevec®) produces responses in patients with relapsed/refractory Waldenstrom's macroglobulinemia [abstract]. Blood. 2007;110:759a. Abstract 2575.
13. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood. 2007;109:1185-92.
14. Hunter Z, Branagan AR, Ditzel Santos D, et al. High levels of soluble immunoregulatory receptors in patients with Waldenstrom's macroglobulinemia [abstract]. Blood. 2004;104:303b. Abstract 4881.
15. Jacquot S. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol Res. 2000;21:23-30.
16. Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol. 2004;173:3901-3908.
17. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenström macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 2002;100:1505-1507.
18. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004;104:2134-2142.
19. Santos DD, Ho AW, Tournilhac O, et al. Establishment of BCWM. 1 cell line for Waldenstrom's Macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007; 35:1366-1375.
20. Kirshenbaum AS, Akin C, Wu Y, et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI. Leuk Res. 2003;27:677-682.
21. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clin Lymph Myeloma. 2006;6:478-483.
22. Tassone P, Neri P, Kutok JL, et al. A SCID-hu in vivo model of human Waldenstrom's macroglobulinemia. Blood. 2005;106:1341-1345.
23. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380-383.
24. van Oers MH, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood. 1993;82:3430-3436.
25. Kok M, Bonfrer JM, Korse CM, et al. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol. 2003;24:53-60.
26. Ranheim EA, Cantwell MJ, KippsTJ. Expression of CD27 and its ligand CD70 on chronic lymphocytic leukemia cells. Blood. 1995;85:3556-3565.
27. Wideny D, Gundapp G, Said JW, et al. Aberrant expression of CD27 and soluble CD27 in HIV infection and in AIDS associated lymphoma. Clin Immunol. 1999;93:114-123.
28. Tak PP, Hintzen RQ, Tuenissen JJ, et al. Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol. 1996;80: 129-138.
29. Font J, Pallares L, Martorell J, et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1996;81:239-243.
30. Gattorno M, Prigione I, Vignola S, et al. Levels of soluble CD27 in sera and synovial fluid and its expression on memory T cells in patients with juvenile idiopathic arthritides. Clin Exp Rheumatol. 2002;20:863-866.
31. Prokocimer M, Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia and lymphoproliferative disorders. Am J Clin Pathol. 1981;75:35-38.
32. Molin D, Fischer M, Xiang Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol. 2001;114:616-623.
33. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002;119: 122-124.
34. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer. 1999;79:451-455.
35. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007;35:434-442.
36. Prasad KVS,Ao Z, Yoon Y, et al. CD27, a member of the tumor necrosis receptor family, induces apoptosis and binds to Siva, a proaptotic protein. Proc Natl Acad Sci U SA. 1997;94:6346-6351.
37. Py B, Slomianny C, Auberger P, Petit PX, Benichou S. Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J Immunol. 2004; 172:4008-4017.
38. Hatjiharissi E, Adamia S, Cao Y, Ciccarelli BT, Xu L, Treon SP. Novel splice variant transcript of SIVA in Waldenstrom's macroglobulinemia. Hematologica 2007;92:93.
39. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity. 2004;21:477-489.